AbbVie Inc.
ABBV is executing well operationally, but at $266.28 the stock already discounts that execution and then some, leaving a business with real pipeline progress trading at an unjustified 74.46x P/E and above the engine’s $189.95 base value.
AbbVie is not a broken company. It is a very well-run large-cap pharma company whose post-HUMIRA transition is going better than many expected. The evidence is in the numbers. FY26 revenue guidance now stands at $67.6B, up $600M since the start of the year. Q2 revenue was nearly $17B, ahead by $300M, and EBITDA reached $6.72B with a 39.6% margin. The new growth engines are real. SKYRIZI alone is now guided to $21.7B in FY26, and neuroscience has been raised to $12.7B. This is a business with meaningful earnings power.
The problem is the stock already knows all of that. At $266.28, investors are paying 74.46x trailing earnings and 7.27x sales for a company that still has a shrinking HUMIRA franchise, a pressured IMBRUVICA franchise, and a balance sheet carrying $70.8B of debt. That valuation is hard to defend against the actual outputs of the business. FY2025 reported EPS was only $2.37, down 28.5%, net margin was 7.6%, and FCF was just $3.7B. Adjusted figures look much better, but the market is effectively giving full credit to adjusted earnings while discounting very little execution or financing risk.
The case from here depends on three things. First, SKYRIZI/RINVOQ/neuroscience must keep outrunning the decline in HUMIRA and IMBRUVICA. Second, the company must absorb the $0.14 Apogee dilution and still show clean progression in cash earnings. Third, leverage has to come down credibly toward the targeted 2x net leverage within 2-3 years. AbbVie may well execute on all three. But when a stock is 1.2% below its 52-week high and 15.4% above its 200-day average, investors are no longer being paid for that execution risk.
That is why the call stays at SELL despite respect for management. The market is not underestimating the company. It is overpaying for it. A materially lower entry, closer to the engine’s $189.95 base value, would change the conversation.
SKYRIZI, RINVOQ, and neuroscience keep outgrowing expectations, Apogee is viewed as strategically smart, and investors continue valuing ABBV on adjusted EPS rather than reported earnings.
Core execution stays solid, but valuation normalizes toward the engine’s earnings-growth blend as the market stops paying a scarcity premium for a mature pharma cash-flow story.
Multiple compresses toward large-cap pharma norms as HUMIRA and IMBRUVICA declines persist, new launches ramp slower than hoped, and leverage remains above comfort.
Quant call (SELL) diverges from analyst consensus (Strong Buy: 18 buy / 3 hold / 0 sell) — resolve explicitly.
In the short run, the market is a voting machine, but in the long run, it is a weighing machine.
Forward earnings power is materially better than trailing reported EPS suggests, with FY26 adjusted EPS guided to $13.87-$14.07, but even on that cleaner earnings base the stock is being valued as if the post-HUMIRA transition is already fully de-risked. The moat is still real today, anchored by immunology scale, commercial reach, and durable brands like SKYRIZI, RINVOQ, Botox, and Vraylar, but 3-5 years out it is narrower if AbbVie does not keep replenishing exclusivity with new indications and acquisitions. AI is more helper than disruptor here, mainly improving discovery efficiency and trial design rather than creating a structural edge unique to AbbVie, while regulation is a real earnings drag through IRA pricing pressure already visible in IMBRUVICA -29.4%. That leaves a good company with credible forward earnings, but not a stock that should trade at 74.46x trailing earnings near an all-time high.
- Valuation is the problem: 74.46x P/E and 7.27x P/S versus peer averages of 27.6x and 4.3x, while the quant engine’s blended target is $189.95, or -28.7%.
- Operations are solid: FY26 revenue guidance is $67.6B, up $600M since the start of 2026, and Q2 EBITDA reached $6.72B with a 39.6% margin, up 1,500 bps versus Q1.
- Legacy erosion still matters: HUMIRA -36.1% operationally and IMBRUVICA -29.4% operationally, while balance-sheet risk remains elevated at 4.02x debt/EBITDA and a 0.81 current ratio.
- Management raised FY26 revenue guidance by $300M in Q2 and has now raised it by $600M since the start of the year, pointing to better-than-feared replacement of HUMIRA by newer assets.
- Adjusted EPS guidance of $13.87-$14.07 implies strong current earnings power versus reported FY2025 EPS of $2.37, and management said the update includes a $0.10 improvement in the existing business despite $0.14 of Apogee dilution.
- Growth engines are large and visible: SKYRIZI $21.7B FY26 outlook, Neuroscience $12.7B, with Vraylar nearing $4.1B and Botox Therapeutic nearing $4.2B.
- Execution has been consistent lately, with 7 beats in the last 8 quarters, including +1.1%, +2.3%, and +2.3% beats in the last three reported quarters.
- The stock is priced far above what the fundamentals support today: engine methods range from $122.21 DCF to $182.65 P/E multiple, and even the quality-adjusted method is only $260.74, still below the current $266.28.
- Reported profitability is not clean enough to justify a premium this extreme, with FY2025 operating margin only 16.2%, net margin 7.6%, and FCF just $3.7B on $61.2B of revenue.
- Balance-sheet flexibility is not best-in-class for a mega-cap pharma name, with $70.8B of total debt, 4.02x debt/EBITDA, and management only targeting net leverage of 2x within 2-3 years after Apogee closes.
- Some declining franchises are not just cycling but structurally weakening: HUMIRA -36.1% from biosimilars and IMBRUVICA -29.4% from IRA pricing pressure and competitive share loss.
| Metric | Value | Context |
|---|---|---|
| Current price | $266.28 | Near peak valuation, -1.2% vs 52-week high |
| Quant price target | $189.95 | -28.7% vs current, Medium confidence, earnings_growth_blend |
| FY2025 revenue | $61.2B | +3.5% YoY |
| FY2025 EPS | $2.37 | -28.5% YoY, weak base for current multiple |
| FY2025 operating margin | 16.2% | Flat versus prior FY |
| Valuation | 74.46x P/E | 7.27x P/S | Above peer averages of 27.6x and 4.3x |
| FY26 guidance | $67.6B revenue | $13.87-$14.07 adj. EPS | Revenue guide raised $300M in Q2, $600M since start of year |
| Q3 2026 guidance | $17.2B revenue | $3.84-$3.88 adj. EPS | Next read on momentum comes October 30, 2026 |
| Balance sheet | $70.8B debt | 4.02x debt/EBITDA | 0.81 current ratio | Leverage still elevated |
| Cash generation | $3.7B FCF | $3.1B dividends | $0.0B buybacks | Most FCF consumed by dividend |
| Price action | +4.52% in 3M | 15.4% above 200-day avg | Strong setup already reflected in price |
The biggest risk to a SELL call is that the market continues to capitalize AbbVie on forward adjusted EPS near $14.0 and rewards pipeline wins, keeping the stock elevated despite the quant base value of $189.95.
Q3 earnings on October 30, 2026, where investors will focus on the guided $17.2B revenue and $3.84-$3.88 adjusted EPS, plus early read-through on JUVMO/tavapadon launch and Crohn’s regulatory progress for SKYRIZI SC induction.
Ownership is crowded and stable, with the top three institutions holding 70.1% and insiders at only 0.1%, which usually means trading is driven more by factor flows and large-holder conviction than by insider signaling. Short interest is low at 1.11%, or 19.5M shares and 3.3 days-to-cover, so there is little squeeze fuel. Options positioning is mildly supportive, with a positive GEX regime and zero-gamma at $246.44, below spot, which can dampen volatility but does not change the valuation problem.
Still the strategic core, with SKYRIZI FY26 outlook of $21.7B carrying the replacement story while HUMIRA -36.1% continues to shrink.
Management raised the FY26 outlook to $12.7B, with Vraylar nearing $4.1B and Botox Therapeutic nearing $4.2B, making this a major second growth leg.
Pressure is visible in IMBRUVICA -29.4% operationally from IRA pricing and competition, which reduces diversification quality.
The 2024 Q3 call flagged a $200M aesthetics guide cut, mainly Juvederm weakness in China and softer U.S. demand, showing this bucket is more cyclical and less reliable.
Detailed geographic revenue was not provided in the source set; U.S. reimbursement and IRA pricing remain more important to the thesis than geographic mix right now.
AbbVie posted a solid Q2 beat and raised FY26 revenue guidance.
Management has earned decent credibility. On the 2024 Q3 call, AbbVie guided FY24 revenue to about $56.0B, adjusted EPS to $10.90-$10.94, and said it was “very confident” in robust mid-single-digit growth for 2025 while targeting 2.0x net leverage by end-2026. Since then, the company has mostly delivered on the strategic direction, replacing HUMIRA with newer growth assets, raising FY26 revenue guidance twice to $67.6B, building a $21.7B SKYRIZI outlook, and posting 7 beats in the last 8 quarters. The weak spot is that FY2025 reported EPS fell to $2.37, down 28.5%, and FCF was only $3.7B, so the bridge from operating momentum to clean GAAP-like earnings and cash has been messier than the headline adjusted narrative. Direction has not changed materially, but the business has become more dependent on execution in newer franchises and acquired assets.
Based on this momentum, we are raising our full year revenue guidance by 300 million. And have now raised total revenue by 600 million since the start of the year.
We are updating our full year adjusted earnings per share guidance to between $13.87 and $14.07. This update reflects a $0.10 improvement in the outlook of our existing business.
Turning to the third quarter. We anticipate net revenues of approximately $17.2 billion. We also forecast adjusted earnings per share between $3.84 and $3.88.
We achieved adjusted earnings per share of $3.65 which is $0.06 above our guidance midpoint. Total net revenues were nearly $17 billion beating our expectations by 300 million and reflecting robust sales growth of 10.2%.
We do not expect a material impact to our robust outlook in psoriasis from existing or new therapies, given SKYRIZI's very distinct profile.
AbbVie’s moat comes from scale in immunology and neuroscience, payer access, physician relationships, manufacturing depth, and the ability to expand drugs across multiple indications. That moat is durable in the near term because SKYRIZI and RINVOQ are still taking share and management says it sees no material threat to SKYRIZI’s psoriasis outlook, but durability is lower over 3-5 years than it was in the HUMIRA era because more value now depends on continuous pipeline replenishment and M&A execution.
Capital allocation is mixed. AbbVie returned $3.1B in dividends on just $3.7B of FCF and did $0.0B of buybacks, which is prudent given $70.8B of debt but limits flexibility. Capex was only $0.3B, so this is not a capital-intensive story, yet the Apogee deal adds dilution of $0.14 to FY26 EPS and delays the path to the targeted 2x net leverage within 2-3 years.
ABBV rates SELL, Medium conviction. This is a good business and a credible management team, but the stock is priced like a great business with little room for error. At $266.28, the market is capitalizing forward optimism while ignoring that legacy erosion, leverage, and valuation still matter. A move closer to the quant target of $189.95, or evidence of stronger cash conversion with lower leverage, would be needed to change the call. Until then, the right move is to avoid chasing a high-quality story at a stretched price.
≣ Full research note tap to expand
Executive Summary
SELL, Medium conviction. Rated SELL, Medium conviction. AbbVie’s underlying business is stronger than the bears expected, with FY26 revenue now guided to $67.6B and adjusted operating margin approaching 47%, but the stock is priced for near-flawless delivery while HUMIRA and IMBRUVICA are still shrinking sharply and leverage remains meaningful. With shares 1.2% below the 52-week high and 15.4% above the 200-day average, the setup looks late, not early.
Investment Thesis
AbbVie is not a broken company. It is a very well-run large-cap pharma company whose post-HUMIRA transition is going better than many expected. The evidence is in the numbers. FY26 revenue guidance now stands at $67.6B, up $600M since the start of the year. Q2 revenue was nearly $17B, ahead by $300M, and EBITDA reached $6.72B with a 39.6% margin. The new growth engines are real. SKYRIZI alone is now guided to $21.7B in FY26, and neuroscience has been raised to $12.7B. This is a business with meaningful earnings power.
The problem is the stock already knows all of that. At $266.28, investors are paying 74.46x trailing earnings and 7.27x sales for a company that still has a shrinking HUMIRA franchise, a pressured IMBRUVICA franchise, and a balance sheet carrying $70.8B of debt. That valuation is hard to defend against the actual outputs of the business. FY2025 reported EPS was only $2.37, down 28.5%, net margin was 7.6%, and FCF was just $3.7B. Adjusted figures look much better, but the market is effectively giving full credit to adjusted earnings while discounting very little execution or financing risk.
The case from here depends on three things. First, SKYRIZI/RINVOQ/neuroscience must keep outrunning the decline in HUMIRA and IMBRUVICA. Second, the company must absorb the $0.14 Apogee dilution and still show clean progression in cash earnings. Third, leverage has to come down credibly toward the targeted 2x net leverage within 2-3 years. AbbVie may well execute on all three. But when a stock is 1.2% below its 52-week high and 15.4% above its 200-day average, investors are no longer being paid for that execution risk.
That is why the call stays at SELL despite respect for management. The market is not underestimating the company. It is overpaying for it. A materially lower entry, closer to the engine’s $189.95 base value, would change the conversation.
Key Metrics
| Metric | Value | Context | ||
|---|---|---|---|---|
| Current price | $266.28 | Near peak valuation, -1.2% vs 52-week high | ||
| Quant price target | $189.95 | -28.7% vs current, Medium confidence, earnings_growth_blend | ||
| FY2025 revenue | $61.2B | +3.5% YoY | ||
| FY2025 EPS | $2.37 | -28.5% YoY, weak base for current multiple | ||
| FY2025 operating margin | 16.2% | Flat versus prior FY | ||
| Valuation | 74.46x P/E | 7.27x P/S | Above peer averages of 27.6x and 4.3x | |
| FY26 guidance | $67.6B revenue | $13.87-$14.07 adj. EPS | Revenue guide raised $300M in Q2, $600M since start of year | |
| Q3 2026 guidance | $17.2B revenue | $3.84-$3.88 adj. EPS | Next read on momentum comes October 30, 2026 | |
| Balance sheet | $70.8B debt | 4.02x debt/EBITDA | 0.81 current ratio | Leverage still elevated |
| Cash generation | $3.7B FCF | $3.1B dividends | $0.0B buybacks | Most FCF consumed by dividend |
| Price action | +4.52% in 3M | 15.4% above 200-day avg | Strong setup already reflected in price |
Financial Strength
AbbVie’s financial profile is acceptable, not pristine. The business can generate large EBITDA in a strong quarter, and adjusted operating margin approaching 47% suggests the underlying portfolio is quite profitable, but that does not fully show up in the FY2025 reported results or free cash flow. $70.8B of debt and 4.02x debt/EBITDA are high for a stock trading at a premium multiple, and the 0.81 current ratio leaves less short-term cushion than ideal. The dividend looks supported for now, but with $3.1B of dividends against $3.7B of FCF, balance-sheet repair matters more than shareholder optionality.
Competitive Position
AbbVie’s moat comes from scale in immunology and neuroscience, payer access, physician relationships, manufacturing depth, and the ability to expand drugs across multiple indications. That moat is durable in the near term because SKYRIZI and RINVOQ are still taking share and management says it sees no material threat to SKYRIZI’s psoriasis outlook, but durability is lower over 3-5 years than it was in the HUMIRA era because more value now depends on continuous pipeline replenishment and M&A execution.
Management & Guidance
Management is guiding to a strong FY26, with revenue of about $67.6B, adjusted EPS of $13.87-$14.07, adjusted operating margin approaching 47%, and Q3 revenue of about $17.2B with adjusted EPS of $3.84-$3.88. That guidance carries reasonable credibility because AbbVie has beaten consensus in 7 of the last 8 quarters, including three straight beats in 2026, and management has now lifted the FY26 revenue view twice. The caveat is that guidance quality is better on adjusted operating metrics than on balance-sheet simplification or clean cash conversion, especially with Apogee adding $0.14 of dilution and leverage relief pushed over 2-3 years.
Segment Analysis
- Immunology (N/A): Still the strategic core, with SKYRIZI FY26 outlook of $21.7B carrying the replacement story while HUMIRA -36.1% continues to shrink.
- Neuroscience (N/A): Management raised the FY26 outlook to $12.7B, with Vraylar nearing $4.1B and Botox Therapeutic nearing $4.2B, making this a major second growth leg.
- Oncology / Hematologic oncology (N/A): Pressure is visible in IMBRUVICA -29.4% operationally from IRA pricing and competition, which reduces diversification quality.
- Aesthetics and other (N/A): The 2024 Q3 call flagged a $200M aesthetics guide cut, mainly Juvederm weakness in China and softer U.S. demand, showing this bucket is more cyclical and less reliable.
- Geography (N/A): Detailed geographic revenue was not provided in the source set; U.S. reimbursement and IRA pricing remain more important to the thesis than geographic mix right now.
Capital Allocation
Capital allocation is mixed. AbbVie returned $3.1B in dividends on just $3.7B of FCF and did $0.0B of buybacks, which is prudent given $70.8B of debt but limits flexibility. Capex was only $0.3B, so this is not a capital-intensive story, yet the Apogee deal adds dilution of $0.14 to FY26 EPS and delays the path to the targeted 2x net leverage within 2-3 years.
Management Execution & Track Record
Management has earned decent credibility. On the 2024 Q3 call, AbbVie guided FY24 revenue to about $56.0B, adjusted EPS to $10.90-$10.94, and said it was “very confident” in robust mid-single-digit growth for 2025 while targeting 2.0x net leverage by end-2026. Since then, the company has mostly delivered on the strategic direction, replacing HUMIRA with newer growth assets, raising FY26 revenue guidance twice to $67.6B, building a $21.7B SKYRIZI outlook, and posting 7 beats in the last 8 quarters. The weak spot is that FY2025 reported EPS fell to $2.37, down 28.5%, and FCF was only $3.7B, so the bridge from operating momentum to clean GAAP-like earnings and cash has been messier than the headline adjusted narrative. Direction has not changed materially, but the business has become more dependent on execution in newer franchises and acquired assets.
Positioning & Flows
Ownership is crowded and stable, with the top three institutions holding 70.1% and insiders at only 0.1%, which usually means trading is driven more by factor flows and large-holder conviction than by insider signaling. Short interest is low at 1.11%, or 19.5M shares and 3.3 days-to-cover, so there is little squeeze fuel. Options positioning is mildly supportive, with a positive GEX regime and zero-gamma at $246.44, below spot, which can dampen volatility but does not change the valuation problem.
Bull Case
- Management raised FY26 revenue guidance by $300M in Q2 and has now raised it by $600M since the start of the year, pointing to better-than-feared replacement of HUMIRA by newer assets.
- Adjusted EPS guidance of $13.87-$14.07 implies strong current earnings power versus reported FY2025 EPS of $2.37, and management said the update includes a $0.10 improvement in the existing business despite $0.14 of Apogee dilution.
- Growth engines are large and visible: SKYRIZI $21.7B FY26 outlook, Neuroscience $12.7B, with Vraylar nearing $4.1B and Botox Therapeutic nearing $4.2B.
- Execution has been consistent lately, with 7 beats in the last 8 quarters, including +1.1%, +2.3%, and +2.3% beats in the last three reported quarters.
Bear Case
- The stock is priced far above what the fundamentals support today: engine methods range from $122.21 DCF to $182.65 P/E multiple, and even the quality-adjusted method is only $260.74, still below the current $266.28.
- Reported profitability is not clean enough to justify a premium this extreme, with FY2025 operating margin only 16.2%, net margin 7.6%, and FCF just $3.7B on $61.2B of revenue.
- Balance-sheet flexibility is not best-in-class for a mega-cap pharma name, with $70.8B of total debt, 4.02x debt/EBITDA, and management only targeting net leverage of 2x within 2-3 years after Apogee closes.
- Some declining franchises are not just cycling but structurally weakening: HUMIRA -36.1% from biosimilars and IMBRUVICA -29.4% from IRA pricing pressure and competitive share loss.
Valuation & Price Target
Engine price target $189.95 (-28.7% vs current), Medium confidence.
- P/E Multiple: $182.65 (25% weight)
- P/S Multiple: $149.91 (20% weight)
- Quality-adjusted: $260.74 (20% weight)
- DCF: $122.21 (6% weight)
This call aligns with the quant baseline SELL. The reason is simple: operating execution is good, but the stock price is richer than the business quality warrants today. The engine’s blended target is $189.95, with underlying methods at $182.65 on P/E, $149.91 on P/S, $122.21 on DCF, and only the quality-adjusted method at $260.74, still below the current $266.28. Peer multiple support is weak because the peer set has wide dispersion of 7.7x, and ABBV already trades at 74.46x versus the peer average 27.6x. Sell-side consensus is still Strong Buy with 18 buy / 3 hold / 0 sell, but that is low-signal context here and does not offset the valuation excess, leverage of 4.02x debt/EBITDA, and stock positioning near the high.
Risk Assessment
Risk score 51/100 (Moderate). The biggest risk to a SELL call is that the market continues to capitalize AbbVie on forward adjusted EPS near $14.0 and rewards pipeline wins, keeping the stock elevated despite the quant base value of $189.95.
The Bottom Line
ABBV rates SELL, Medium conviction. This is a good business and a credible management team, but the stock is priced like a great business with little room for error. At $266.28, the market is capitalizing forward optimism while ignoring that legacy erosion, leverage, and valuation still matter. A move closer to the quant target of $189.95, or evidence of stronger cash conversion with lower leverage, would be needed to change the call. Until then, the right move is to avoid chasing a high-quality story at a stretched price.
Go deeper in the app
Live charts, options analytics, the full earnings-call breakdown, price alerts, and every other stock — updated in real time.
Get Tickr